NGS 樣品製備的全球市場：COVID-19 的增長、趨勢、影響、預測（2021-2026）
NGS Sample Preparation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
在預測期內，全球 NGS 樣品製備市場規模預計將以 12.4% 的複合年增長率增長。
市場的增長被認為主要是由於傳染病流行率增加、測序成本降低以及 NGS 平台的技術進步等因素。 NGS 技術空前增長背後的關鍵特徵之一是 NGS 平台的進步，這些平台可用於生物醫學、基礎研究和農業的各個領域。
單次運行 NGS 技術可同時產生數千或數百萬個短重疊序列，這是傳統測序儀無法實現的。預計這些因素將在預測期內促進市場增長。然而，NGS 樣品製備設備的高成本和與 NGS 樣品製備相關的嚴格規定會阻礙市場增長。
本報告調查了全球 NGS 樣品製備市場、市場概況、性能、COVID-19 的影響、按產品類別、應用、最終用戶、地區、競爭形勢、主要我們提供公司簡介等的市場分析。
The NGS sample preparation market is projected to register a CAGR 12.4% during the forecast period.
One of the most significant global threats in modern history is the ongoing COVID-19 pandemic and has resulted in significant social and economic consequences. The World Health Organization (WHO) declared it a pandemic as 118,000 cases reported from 110 countries on the 11th March 2020. In the current situation, it has affected more than 200 countries worldwide. Thus, an effective and quick sequencing technologies must be developed in order to rebuild the genomic sequence of SARS-CoV-2, which is the etiological agent of COVID-19. It has been critical in the development of diagnostic molecular tests as well as the development of efficient tactics and strategies to slow the spread of the pandemic. Hence there is no way COVID-19 can harm the NGS sample preparation market. In August 2020, Helix Laboratory received the United States Food and Drug Administration emergency use authorization for NGS based COVID-19 test, which is designed to detect the SARS-CoV-2 spike protein gene in upper respiratory specimens. Thus, in the context of the ongoing pandemic, the NGS sample preparation market is expected to be positively impacted by COVID-19.
NGS sequencing technologies have swiftly become the method of choice in virology for a wide range of applications, including the detection of novel viruses from metagenomic samples, reconstruction of whole or almost complete viral genome sequences, and viral evolution and quasispecies analysis. One of the most significant benefit of NGS-based techniques is that full-length viral genomes may be rebuilt from culture-enriched viral preparations or straight from clinical samples, even for unknown or poorly characterized viruses. Both second and third generation NGS technologies have been effectively employed in the context of SARS-CoV-2, and many specialized library preparation techniques have been produced independently by various manufacturers.
The studied market growth can largely be attributed to factors, such rising prevalence of infectious diseases, reduced cost of sequencing and technical advancements in NGS platforms. NGS technologies have replaced the traditional sequencing methods because of low cost and high efficiency of sequencing.
One of the key parameters in the unprecedented growth of NGS technologies is the advancement in the NGS platforms which can be used in different areas of biomedical, basic research and agriculture. Ilumina's NextSeq 1000 & 2000 sequencer can provide a maximum of 400M to 1.1B reads per run with a maximum read length of 2 x 150 bp. Advancement in the sequencing technologies have made it possible to study the genome at a cellular level too. In a single run of NGS technique, thousands or millions of short overlapping sequences are produced simultaneously which is not possible with traditional sequencers. Such factors are expected to boost the market growth during the forecast period. However, high costs of NGS sample preparation equipment and strict regulation associated with NGS sample preparation might hinder the growth of the market.
The Diagnostics segment is expected to witness signficant growth over the forecast period. Sequencing of individual cancer-patient genomes is been carried out using NGS base genomic sequencing and it has become faster and less expensive with each passing year, allowing NGS to be utilized not just in research but also in clinical practice. In August 2020, for the use of NGS, the European Society for Medical Oncology (ESMO) has proposed three levels of recommendations. ESMO supports routine use of NGS on tumor samples in advanced non-squamous non-small-cell lung cancer (NSCLC), cholangiocarcinoma, ovarian cancers, and prostate cancers based on the available data. In colon cancers, NGS could be an alternative to PCR. NGS can be suitable for identification of multiple genes and their mutations concurrently by sequencing millions of DNA reads and driving therapeutic decision making.
The International Agency for Research on Cancer (IARC) Globocan 2020, estimated that the global cancer burden has reached 19.3 million cases and 10 million cancer deaths in 2020. IARC estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. As the prevalence rate of cancer is increasing, there is need of much more diagnostic tools which can be used for effective and reliable diagnosis.
Diagnostic tools play an important role in the detection of viruses, fungi, bacteria and other pathogens. With increased burden of COVID 19, there is a high need of diagnostic tools which can be used at lower costs and deliver better outcomes. New corona virus strains and other pathogens can be identified in an effective way using unbiased technique. Growing concern about novel SARS-CoV-2 coronavirus variants spreading swiftly, such as the B.1.1.7 strain in the United Kingdom and the B1.351 strain in South Africa given in a study published on Centers for Disease Control and Prevention (2021), underscores the need for additional sequencing to discover mutation rapidly and limit the spread of new strains. NGS can offer information on how to trace down different virus transmission routes around the world, in order to prevent the emergence of new strains, and how to identify viral mutations that can affect the detection process and vaccine potency.
One more factor which is driving the market for NGS sample preparation is increased number of genomic research projects globally. As genomic research can give deep information to understand biology, human history, and health disparities along with recognition of several important clinical significances. Exome and genome sequencing have lately enabled wide genetic testing on an individual patient basis within a clinically meaningful timeframe, because of advancements in sequencing technology. Thus, NGS plays an important role in diagnosis and monitoring of various infectious diseases, which may fuel the market growth.
Furthermore, in Aug 2020, Guardant Health Inc. received the United States Food and Drug Administration (FDA) approval for Guardant360 CDx, which uses two combined technology, Liquid biopsy and NGS in one diagnostic test. Hence, with the increasing products approval related to NGS diagnostic for COVID-19 may surge the growth of the studied market.
North America accounted for a high share in the global NGS sample preparation because of need of diagnostics tool for identifying health disparities and rising burden and increasing spread of the COVID 19 pandemic and chronic diseases in the region are the major factors driving the NGS sample preparation market in North America. According to GLOBOCON 2020, around 2,281,658 new cancer cases were diagnosed in the United States.
Next generation sequencing market is gaining importance as it has a huge market in clinical diagnostic test, especially with the high impact of COVID 19 pandemic in this region. The new variants of COVID 19 seem to spread more rapidly which can increase the rate of COVID 19 spread. It will put addition strain on healthcare resources and can potentially leads to more deaths if number of cases increases. The Centers for Disease Control and Prevention monitors multiple variants that are circulating in the United States and estimates their prevalence at the national and regional levels. As per Centers for Disease Control and Prevention (2021), variant B.1.1.7 is the most common variant across the country.
Furthermore, in June 2020, Illumina, Inc. received emergency use authorization from the United States Food and Drug Administration COVID-19 diagnostic test utilizing next generation sequence technology. The FDA approved the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected by their healthcare provider from individuals suspected of having COVID-19.
Furthermore, increased funding from the federal government and private players, as well as increased adoption of NGS technology by non-government and government bodies, are expected to drive market growth.
Top companies in NGS sample preparation in the Global market are Illumina Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Inc. and PerkinElmer.
New product launches and strategic mergers and acquisitions are the key strategies of the players in this market. The following are some of the most recent developments:
In July 2020, Illumina Inc. welcomed Enancio technology to reduce genomic data storage and transfer costs associated with big data. DRAGEN ORA (formerly Enancio's Lena) lossless genomic compression is available on-instrument with the NextSeq 1000/2000 Sequencing System and also on the DRAGEN server v3.8. In addition, Qiagen launched NGS panels and liquid biopsy solutions with integrated bioinformatics in 2019 to drive cancer research advancements. Also, in Mar 2018, QIAGEN and Natera have partnered to produce cell-free DNA assays for QIAGEN's GeneReader NGS System. The company also prioritizes the development of new items and the enhancement of its current product portfolio. Several companies collaborate each year to benefit from and deliver the finest outcomes from new technologies in the NGS market. With these developments, companies can increase their market presence and acquire a competitive advantage, which is pushing market growth.